See more : FOXTRON VEHICLE TECHS CO LTD (2258.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Bora Pharmaceuticals Co., LTD. (6472.TW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bora Pharmaceuticals Co., LTD., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Aedifica SA (AEDFF) Income Statement Analysis – Financial Results
- Mediaset España Comunicación, S.A. (TL5.MC) Income Statement Analysis – Financial Results
- Rafael Microelectronics, Inc. (6568.TWO) Income Statement Analysis – Financial Results
- Universal Vision Biotechnology Co., Ltd. (3218.TWO) Income Statement Analysis – Financial Results
- Guangdong DP Co.,Ltd. (300808.SZ) Income Statement Analysis – Financial Results
Bora Pharmaceuticals Co., LTD. (6472.TW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bora-corp.com
About Bora Pharmaceuticals Co., LTD.
Bora Pharmaceuticals Co., LTD. researches and develops, manufactures, distributes, and sells pharmaceuticals worldwide. The company operates through Sales, Contract Development & Manufacturing Organization, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services, including clinical and commercial manufacturing, pharmaceutical development, packaging and serialization, analytical and microbiology testing, and regulatory affairs services. In addition, it provides food and vitamin supplements, and skincare products; and biotechnical services. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 14.20B | 10.49B | 4.90B | 1.80B | 1.53B |
| Cost of Revenue | 7.21B | 7.58B | 3.23B | 1.10B | 886.18M |
| Gross Profit | 6.99B | 2.91B | 1.67B | 703.88M | 643.03M |
| Gross Profit Ratio | 49.23% | 27.76% | 34.12% | 39.11% | 42.05% |
| Research & Development | 298.16M | 129.08M | 41.27M | 36.65M | 39.65M |
| General & Administrative | 996.85M | 601.41M | 406.16M | 299.91M | 159.13M |
| Selling & Marketing | 447.09M | 260.12M | 178.36M | 141.24M | 99.42M |
| SG&A | 1.44B | 861.52M | 584.52M | 441.16M | 258.54M |
| Other Expenses | 0.00 | 26.55M | 31.59M | 3.43M | 0.00 |
| Operating Expenses | 1.74B | 990.60M | 625.79M | 477.81M | 305.60M |
| Cost & Expenses | 8.95B | 8.57B | 3.85B | 1.57B | 1.19B |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 12.09M |
| Interest Expense | 171.24M | 108.73M | 53.62M | 21.97M | 14.54M |
| Depreciation & Amortization | 485.11M | 325.19M | 210.17M | 141.03M | 107.19M |
| EBITDA | 5.73B | 2.27B | 1.29B | 370.54M | 452.04M |
| EBITDA Ratio | 40.38% | 21.67% | 26.28% | 20.59% | 29.56% |
| Operating Income | 5.25B | 1.95B | 1.08B | 229.51M | 344.85M |
| Operating Income Ratio | 36.97% | 18.57% | 21.99% | 12.75% | 22.55% |
| Total Other Income/Expenses | -1.18B | -82.18M | -22.02M | 365.89M | -19.50M |
| Income Before Tax | 4.06B | 1.84B | 1.02B | 595.40M | 325.35M |
| Income Before Tax Ratio | 28.62% | 17.53% | 20.90% | 33.09% | 21.28% |
| Income Tax Expense | 992.23M | 438.48M | 274.23M | 16.97M | 20.32M |
| Net Income | 3.03B | 1.39B | 749.74M | 578.43M | 305.03M |
| Net Income Ratio | 21.34% | 13.26% | 15.30% | 32.14% | 19.95% |
| EPS | 30.20 | 14.26 | 7.73 | 6.04 | 3.40 |
| EPS Diluted | 29.26 | 14.13 | 7.71 | 6.00 | 3.40 |
| Weighted Avg Shares Out | 100.34M | 97.60M | 77.85M | 95.77M | 89.68M |
| Weighted Avg Shares Out (Dil) | 103.56M | 98.70M | 78.08M | 96.50M | 89.73M |
Source: https://incomestatements.info
Category: Stock Reports